MetaCap

Abbott Laboratories (ABT) vs Merck (MRK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Merck (MRK) has outperformed Abbott Laboratories (ABT) over the past year, gaining 36.8% versus a loss of 19.6%. Over five years, MRK leads with a +68.9% price change compared with -18.2% for ABT. Merck is the larger company by market cap ($329.65 billion vs $178.39 billion), about 1.8 times the size, while Abbott Laboratories is growing revenue faster (+5.7% vs +1.3%).

On valuation, Merck trades at a lower forward P/E (14.9x vs 17.3x for Abbott Laboratories). Merck offers the higher dividend yield (2.51% vs 2.45%). Merck converts more of its revenue into profit, with a net margin of 28.1% versus 14.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABT-19.60%MRK+36.78%
+65%+12%-40%
Nov 21, 20251 yearNov 20, 2026
ABT-18.80%MRK+65.70%
+95%+28%-40%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABT versus MRK key metrics
MetricABTMRK
Share price$103.00$133.72
Market cap$178.39B$329.65B
1-day change-0.84%+0.69%
YTD return-17.79%+27.04%
1-year return-19.60%+36.78%
5-year return-18.18%+68.92%
P/E ratio (TTM)38.43135.07
Forward P/E17.3514.92
EPS (TTM)$2.68$0.99
Dividend yield2.45%2.51%
Annual dividend$2.52$3.36
Revenue (latest FY)$44.33B$65.01B
Revenue growth (YoY)+5.67%+1.31%
Net income (latest FY)$6.52B$18.25B
Gross margin56.42%74.80%
Operating margin18.17%—
Net margin14.72%28.08%
52-week high$129.85$156.92
52-week low$81.97$96.06
Distance from 52-week high-20.68%-14.78%
Analyst consensusbuybuy
Avg. price target upside+15.45%+20.80%
Average volume8.89M9.81M
Shares outstanding1.73B2.47B
Employees122,00073,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRK has outperformed ABT by 56.4 percentage points over the past year.
  • Merck trades at a higher earnings multiple (135.1x vs 38.4x trailing P/E).
  • Merck is more profitable, keeping 28.1 cents of every revenue dollar as net income versus 14.7 cents for Abbott Laboratories.

About Abbott Laboratories

ABT stock →

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees

About Merck

MRK stock →

Merck & Co., Inc. operates as a healthcare company worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 73,000 employees

ABT vs MRK FAQ

Which is bigger, Abbott Laboratories or Merck?

Merck (MRK) is larger, with a market capitalization of $329.65B compared with $178.39B for Abbott Laboratories (ABT).

Which stock has performed better over the past year, ABT or MRK?

MRK returned +36.78% over the past 12 months, compared with -19.60% for ABT (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ABT or MRK?

ABT has the lower trailing P/E at 38.4, versus 135.1 for MRK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Abbott Laboratories or Merck?

Merck has the higher yield at 2.51%, compared with 2.45% for Abbott Laboratories.

Are Abbott Laboratories and Merck in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons